A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, the field mostly relies on the prediction of HLA class I and class II SARS-CoV-2 peptide epitopes and directed peptide mapping of T cell reactive epitopes to instruct vaccine design17–20.”
From Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J., & Münch, C. (2020) · Nature · doi:10.1038/s41586-020-2332-7 · Cited by 1,010
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
The Cellosaurus, a Cell-Line Knowledge Resource
Bairoch, A. (2018) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.18-2902-002 · Cited by 807
Tan, A. T., Linster, M., Tan, C. W., Le Bert, N., Chia, W. N., Kunasegaran, K., Zhuang, Y., Tham, C. Y. L., Chia, A., Smith, G. J. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108728 · Cited by 740
Gonzalez-Galarza, F. F., McCabe, A., Santos, E. J. M. D., Jones, J., Takeshita, L., Ortega-Rivera, N. D., Cid-Pavon, G. M. D., Ramsbottom, K., Ghattaoraya, G., Alfirevic, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1029 · Cited by 731
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600
Research works printed but not linked: 57
- Wang, 2022, Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5, Nature, 608, 603, 10.1038/s41586-022-05053-w · DOI · Paper page
- Nemet, 2022, Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection, N Engl J Med, 386, 492, 10.1056/NEJMc2119358 · DOI · Paper page
- McLean, 2022, The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 Vaccines, mBio, 13, 10.1128/mbio.02979-21 · DOI · Paper page
- Kurhade, 2022, Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster, Nat Med
- Wang, 2023, Antibody Response to Omicron BA.4-BA.5 Bivalent Booster, N Engl J Med, 388, 567, 10.1056/NEJMc2213907 · DOI · Paper page
- Poland, 2021, The need for broadly protective COVID-19 vaccines: beyond S-only approaches, Vaccine, 39, 4239, 10.1016/j.vaccine.2021.06.028 · DOI
- Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, e8
- Perez-Alos, 2022, Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors, Nat Commun, 13, 1614, 10.1038/s41467-022-29225-4 · DOI · Paper page
- Sette, 2023, T cell responses to SARS-CoV-2, Annu Rev Immunol, 41, 343, 10.1146/annurev-immunol-101721-061120 · DOI · Paper page
- Tarke, 2022, Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors, Int J Mol Sci, 23, 10.3390/ijms23137155 · DOI
- Moss, 2022, The T cell immune response against SARS-CoV-2, Nat Immunol, 23, 186, 10.1038/s41590-021-01122-w · DOI · Paper page
- Ferretti, 2020, Unbiased Screens Show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein, Immunity, 53, 1095, 10.1016/j.immuni.2020.10.006 · DOI · Paper page
- Keeton, 2022, T cell responses to SARS-CoV-2 spike cross-recognize Omicron, Nature, 603, 488, 10.1038/s41586-022-04460-3 · DOI · Paper page
- GeurtsvanKessel, 202272202, Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients, Sci Immunol
- Yu, 2023, The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development, Emerg Microbes Infect, 12, e2164219, 10.1080/22221751.2022.2164219 · DOI
- Yan, 2022, Structural biology of SARS-CoV-2: open the door for novel therapies, Signal Transduct Target Ther, 7, 26, 10.1038/s41392-022-00884-5 · DOI · Paper page
- Jahirul Islam, 2023, A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites, Immunobiology, 228, 10.1016/j.imbio.2022.152302 · DOI
- Zandi, 2022, The role of SARS-CoV-2 accessory proteins in immune evasion, Biomed Pharmacother, 156, 10.1016/j.biopha.2022.113889 · DOI
- Bello-Perez, 2023, SARS-CoV-2 ORF8 accessory protein is a virulence factor, mBio., 14, 10.1128/mbio.00451-23 · DOI
- Ovsyannikova, 2004, Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides, J Virol, 78, 42, 10.1128/JVI.78.1.42-51.2004 · doi:10.1128/jvi.78.1.42-51.2004
- Johnson, 2009, Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development, Vaccine, 28, 38, 10.1016/j.vaccine.2009.09.126 · DOI
- Crooke, 2021, Identification of naturally processed Zika virus peptides by mass spectrometry and validation of memory T cell recall responses in Zika convalescent subjects, PLoS One, 16, e0252198, 10.1371/journal.pone.0252198 · DOI
- Quach, 2022, Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine, Sci Rep, 12, 15401, 10.1038/s41598-022-19679-3 · DOI
- Crooke, 2020, Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome, Sci Rep, 10, 14179, 10.1038/s41598-020-70864-8 · DOI
- Chu, 2020, Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study, Lancet Microbe, 1, e14, 10.1016/S2666-5247(20)30004-5 · DOI · Paper page
- Chang, 2022, A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants, Viruses, 14, 10.3390/v14071369 · DOI
- Estrella, 2011, A novel in vitro human macrophage model to study the persistence of mycobacterium tuberculosis using Vitamin D(3) and retinoic acid activated THP-1 macrophages, Front Microbiol, 2, 67, 10.3389/fmicb.2011.00067 · DOI
- UniProt, 2021, UniProt: the universal protein knowledgebase in 2021, Nucleic Acids Res, 49, D480, 10.1093/nar/gkaa1100 · DOI · Paper page
- Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res, 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
- Reynisson, 2020, Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data, J Proteome Res, 19, 2304, 10.1021/acs.jproteome.9b00874 · DOI · Paper page
- Nielsen, 2016, NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets, Genome Med, 8, 33, 10.1186/s13073-016-0288-x · DOI · Paper page
- Knierman, 2020, The human leukocyte antigen class II immunopeptidome of the SARS-CoV-2 spike glycoprotein, Cell Rep, 33, 10.1016/j.celrep.2020.108454 · DOI · Paper page
- Vita, 2019, The Immune Epitope Database (IEDB): 2018 update, Nucleic Acids Res, 47, D339, 10.1093/nar/gky1006 · DOI · Paper page
- Bui, 2006, Predicting population coverage of T-cell epitope-based diagnostics and vaccines, BMC Bioinf, 7, 153, 10.1186/1471-2105-7-153 · DOI · Paper page
- Khare, 2021, GISAID's Role in Pandemic Response, China CDC Wkly, 3, 1049, 10.46234/ccdcw2021.255 · DOI · Paper page
- Clark, 2016, GenBank, Nucleic Acids Res, 44, D67, 10.1093/nar/gkv1276 · DOI · Paper page
- Pickett, 2012, Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community, Viruses, 4, 3209, 10.3390/v4113209 · DOI · Paper page
- Sievers, 2011, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega, Mol Syst Biol, 7, 539, 10.1038/msb.2011.75 · DOI · Paper page
- Bui, 2007, Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines, BMC Bioinf, 8, 361, 10.1186/1471-2105-8-361 · DOI · Paper page
- Mannar, 2022, SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization, Nat Commun, 13, 4696, 10.1038/s41467-022-32262-8 · DOI
- Pan, 2021, Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs, Proc Natl Acad Sci U S A, 118, 10.1073/pnas.2111815118 · DOI · Paper page
- Lee, 2020, Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells, Emerg Microbes Infect, 9, 2169, 10.1080/22221751.2020.1827985 · DOI
- Nagler, 2021, Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics, Cell Rep, 35, 10.1016/j.celrep.2021.109305 · DOI · Paper page
- Stanifer, 2020, Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells, Cell Rep, 32, 10.1016/j.celrep.2020.107863 · DOI · Paper page
- Zupin, 2022, Effect of short time of SARS-CoV-2 infection in Caco-2 cells, Viruses, 14, 10.3390/v14040704 · DOI
- Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol Cell Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
- Grifoni, 2020, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell, 181, e15
- Le Bert, 2020, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls, Nature, 584, 457, 10.1038/s41586-020-2550-z · DOI · Paper page
- Prakash, 2021, Genome-Wide B Cell, CD4(+), and CD8(+) T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines, J Immunol, 206, 2566, 10.4049/jimmunol.2001438 · DOI · Paper page
- Meyers, 2021, Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation, npj Vaccines, 6, 71, 10.1038/s41541-021-00331-6 · DOI
- Tada, 2023, Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model, JCI Insight, 8, 10.1172/jci.insight.167306 · DOI
- Pardieck, 2022, A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection, Nat Commun, 13, 3966, 10.1038/s41467-022-31721-6 · DOI
- Heitmann, 2022, A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity, Nature, 601, 617, 10.1038/s41586-021-04232-5 · DOI · Paper page
- Li, 2014, Peptide vaccine: progress and challenges, Vaccines (Basel), 2, 515, 10.3390/vaccines2030515 · DOI · Paper page
- Obermair, 2022, High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape, Sci Adv, 8, 10.1126/sciadv.abl5394 · DOI
- Matchett, 2021, Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity, J Immunol, 207, 376, 10.4049/jimmunol.2100421 · DOI · Paper page
- Jing, 2022, T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components, JCI Insight, 7, 10.1172/jci.insight.158126 · DOI
Cited by
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51959-6 · Cited by 12
Metadata
- Authors
- Ratishvili, T., Quach, H. Q., Haralambieva, I. H., Suryawanshi, Y. R., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 42
- Issue
- 2
- Pages
- 162-174
- ISSN
- 0264-410X
- Cited by
- 6
- References
- 15
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Mayo Clinic
- ICW Healthcare Ventures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides. https://app.cochat.ai/papers/10.1016/j.vaccine.2023.12.024
- The paper
- Ratishvili, T., Quach, H. Q., Haralambieva, I. H., Suryawanshi, Y. R., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A. (2024). A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides. Vaccine. https://doi.org/10.1016/j.vaccine.2023.12.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.